NCT04306510View on ClinicalTrials.gov

A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN

PHASE4TerminatedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

January 21, 2021

Primary Completion Date

March 20, 2024

Study Completion Date

March 20, 2024

Conditions

Hereditary Transthyretin Amyloidosis With Polyneuropthy

Interventions

DRUG

TEGSEDI

SC injection.

Trial Locations (2)

11422

Study Center, Rosedale

M3K0A6

Study Center, Toronto

Sponsors

Lead Sponsor

Akcea Therapeutics

All Listed Sponsors

lead

Akcea Therapeutics

INDUSTRY

NCT04306510 - A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN | Biotech Hunter | Biotech Hunter